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Friedreich ataxia (FRDA), a multisystem autosomal recessive condition, is the most common inherited ataxia in
Caucasians, affecting approximately 1 in 29,000 individuals. The hallmark clinical features of FRDA include progressive
afferent and cerebellar ataxia, dysarthria, impaired vibration sense and proprioception, absent tendon reflexes in lower
limbs, pyramidal weakness, scoliosis, foot deformity and cardiomyopathy. Despite significant progress in the search for
disease modifying agents, the chronic progressive nature of FRDA continues to have a profound impact on the health
and well-being of people with FRDA. At present there is no proven treatment that can slow the progression or
eventual outcome of this life-shortening condition. Thirty-nine expert clinicians located in Europe, Australia, Canada
and USA critically appraised the published evidence related to FRDA clinical care and provided this evidence in a
concise manner. Where no published data specific to FRDA existed, recommendations were based on data related to
similar conditions and/or expert consensus. There were 146 recommendations developed to ensure best practice in
the delivery of health services to people with FRDA. Sixty-two percent of recommendations are based on expert
opinion or good practice indicating the paucity of high-level quality clinical studies in this area. Whilst the development
of these guidelines provides a critical first step in the provision of appropriate clinical care for people with FRDA, it also
highlights the urgency of undertaking high-quality clinical studies that will ensure the delivery of optimum clinical
management and intervention for people with FRDA.
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Friedreich ataxia (FRDA), the most common of the her-
editary ataxias, is an autosomal recessive, multisystem
disorder affecting approximately 1 in 29,000 individuals
and has a carrier frequency of 1 in 85 in individuals of
Caucasian background [1,2]. The hallmark neurological
features of FRDA include progressive afferent and cerebel-
lar ataxia, dysarthria, fixation instability, impaired vibra-
tion sense and proprioception, and pyramidal weakness.
Most affected individuals have absent lower limb reflexes,
but some have retained reflexes and may have spasticity.
Scoliosis, diabetes, foot deformity and cardiomyopathy are
common non-neurological features [3-5]. Pathology re-
lated to FRDA includes degeneration of the dorsal root* Correspondence: martinbd@unimelb.edu.au
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unless otherwise stated.ganglia and posterior columns of the spinal cord, spino-
cerebellar tracts, corticospinal tracts, dentate nuclei of the
cerebellum and the heart [6,7]. FRDA is due to mutations
in FXN [8]. In about 96% of mutant alleles there is homo-
zygosity for a pathological expansion of a GAA trinucleo-
tide repeat in intron one of FXN whilst in the other 4%
there is compound heterozygosity for an intron 1 GAA re-
peat expansion in one allele and a point mutation or dele-
tion in the other [8-10]. The GAA expansion results in a
reduction of frataxin, a mitochondrial membrane protein
involved in iron sulfur protein production, storage and
transport [11,12]. Since the discovery of the molecular
basis underlying this disorder in 1996, there has been an
abundance of studies exploring the nature of the muta-
tion, the role of frataxin, disease progression and disease
modifying agents [11,13-15]. Although no specific therap-
ies have been identified that can alter the course of this
devastating disease, a number of promising compounds
have been identified [11,16]. However the challenge for. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 List of topics included in the clinical management
guidelines
1 Overview of Friedreich Ataxia
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management for the multifaceted issues facing people
with FRDA endures.
In 2003, “Revalidatie Geneeskundige Richtlijn Ataxie
van Friedreich” was written by a special task force under
the auspices of ‘Vereniging Spierziekten Nederland’. These
were the first guidelines that provided an evidence base to
the clinical management of people with FRDA. These
guidelines were subsequently updated and adapted for
international use in September 2007 (http://www.vsn.
nl/hulpverleners/protocol_detail.php?protocol_id=17). In
2009, Ataxia UK launched “Management of ataxia: to-
wards best clinical practice”, developed to provide rec-
ommendations for the management of people with
inherited ataxia, including FRDA (http://www.ataxia.
org.uk/pages/resources-and-publications.html). Whilst
this further initiative was welcomed, it was apparent
that issues specific to FRDA required disease specific
guidelines. Furthermore, it was apparent that the mul-
tiple gaps in evidence surrounding service delivery
may provide a platform for ongoing research.2.15 Rehabilitation








7 Friedreich Ataxia due to compound heterozygosity
for a FXN intron 1 GAA expansion and point
mutation/insertion/deletion
8 Pregnancy issues
9 Quality of life issues
9.1 Overview of quality of life in Friedreich Ataxia
9.2 Mental health issues
9.3 Provision of wheelchairs and seating systems
9.4 Independence issues
9.5 Advance care planning and end of lifeMethod
Assembling the Executive Committee and Specialist
Working Groups
An executive committee (MBD, DL, MP, JBS and LAC)
was convened to oversee the process of guideline develop-
ment. Clinicians with expertise in FRDA were recruited to
contribute to the guidelines through invitations from the
executive. Thirty-nine individuals participated in the writ-
ing of these guidelines. This group advanced the topics
and corresponding clinical questions which would be the
foundation of the guidelines. Specialist working groups
(SWGs) related to specific topics were established. There
were two face-to-face meetings during the guideline de-
velopment phase that were attended by some of the 39
authors, otherwise communication was facilitated by
teleconference and email. Each member of the SWGs
was asked to formally declare any potential conflict of
interest however none were present that required re-
moval of any individual from the writing groups.9.6 Palliative care
9.7 Potential medications/compounds for use in
Friedreich AtaxiaDeveloping topics and clinical questions
An initial topic list was developed by MBD and LAC. This
list was refined by discussion with the executive and the
SWGs (see Table 1 for the final topic list). The specific
topics within the guidelines comprised a description of
the topic, associated natural history, investigations, an
evaluation of the evidence and graded recommendations.
Where possible, clinical review questions were developed
around the PICO framework (patients/population, inter-
vention, comparison and outcome) [17] which formed the
basis of the examination of available evidence.Literature search and evaluation of the literature
A literature review was conducted for each topic. Clin-
ical databases included in the search were PubMed,
MEDLINE, CINAHL, Best Practice, Cochrane Database
of Systematic Reviews, EMBASE and Scopus. Guideline
SWGs evaluated the available evidence according to the
templates developed by the Guidelines International
Table 3 National Health and Medical Research Council




A Body of evidence can be trusted to guide practice:
includes one or more level I studies or several level
II studies with low risk of bias directly applied to the
target population and demonstrating overall
consistency of results.
B Body of evidence can be trusted to guide practice
in most situations: includes one or two studies
rated as II or several level III studies with low risk of
bias, directly applicable to target population, and
demonstrating overall consistency of results.
C Body of evidence provides some support for
recommendation(s) but care should be taken in its
application: includes studies rated as III-3 with a low
risk of bias or level I or II with a moderate risk of
bias, some inconsistency and applicable to target
population with caveats. Population studied is
different from target population however clinically
sensible to apply this evidence to target population.
D Body of evidence is weak and recommendation
must be applied with caution: includes level IV or
level I to IV studies with high risk of bias,




Recommended best practice based on clinical
experience and expert opinion.
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intervention studies.
Grading of evidence and recommendations
A range of international methods of grading of evi-
dence and recommendations were reviewed. These in-
cluded those recommended by the American Academy of
Neurology (AAN) (USA), Scottish Intercollegiate Guide-
lines Network (SIGN), National Institute of Health and
Clinical Excellence (NICE) (UK) and the National Health
and Medical Research Council (NHMRC) Australia. Given
no one method was identified as clearly superior, the evi-
dence and subsequent recommendations were graded ac-
cording to the criteria developed by the NHMRC [18] (see
Table 2 for levels of evidence and Table 3 for grading of
recommendations). In order to indicate the strength of
the body of evidence underscoring the recommendation
and to ascertain if application of the evidence may result
in improved health outcomes, recommendations were al-
located a grading (A-D) according to the level of evidence
(I to IV) available. Recommendations allocated Grade A
were underpinned by a body of evidence that can be
trusted to guide practice. Grade B recommendations in-
cluded those for which a body of evidence can be trusted
to guide practice in most situations. Grade C recommen-
dations comprised those for which the body of evidence
provides some support but care should be taken in its ap-
plication, whereas an allocation of Grade D indicated the
body of evidence underlying the recommendation is weak
and must be applied with caution [18]. Where no clear
Level I, II III or IV evidence was available but where there
was sufficient consensus within the specialist working
group, good practice points (GPP) were provided. A GPP
is the recommended best practice based on clinical experi-
ence and the expert opinion of the SWG. SWGs wereTable 2 Levels of evidence and grading of
recommendations (National Health and Medical
Research Council 1999 [19])
I Evidence obtained from a systematic review of all relevant
randomized controlled trials
II Evidence obtained from at least one properly designed
randomized controlled trial
III-1 Evidence obtained from well-designed pseudo-randomized
controlled trials (alterative allocation or some other method)
III-2 Evidence obtained from comparative studies with concurrent
controls and allocation not randomized (cohort studies),
case–control studies, or interrupted time series with a
control group
III-3 Evidence obtained from comparative studies with historical
control, two or more single-arm studies, or interrupted time
series without a parallel control group
IV Evidence obtained from case series, either post-test or
pre-test and post-test.encouraged to consult widely with colleagues and peers to
ensure consistency of evidence. Every effort was made to
achieve consensus within the group. However for the sec-
tions on Dysarthria and Dysphagia, the recommendations
were sent to the executive group for a final independent
decision. On one occasion (Genetic testing of asymptom-
atic minors) no consensus was reached and both view-
points are presented. Draft iterations of the guidelines
were circulated to all authors involved in producing the
guidelines for comment and feedback. The final draft was
sent to advocacy groups representing individuals with
FRDA.Results
The guidelines comprise 9 sections and 25 subsections
(see Table 1). There are 146 recommendations related to
1) the neurological components of FRDA; 2) the heart,
cardiovascular and respiratory system; 3) scoliosis; 4) dia-
betes mellitus; 5) genetic issues; 6) FRDA due to FXN
compound heterozygosity; 7) pregnancy issues; 8) quality
of life issues. There were three recommendations graded
as A, six graded as B, 28 graded as C, 17 graded as D and
92 GPP. The full guidelines are available on the internet
(http://www.curefa.org/physicians.html). The following
provides a summation of the recommendations from
each topic (Table 4).
Table 4 The neurological components of Friedreich ataxia
1.1 Ataxia
Recommendations Grade
Regular neurological examination should take place, and may guide referral to appropriate specialists in a timely fashion. GPP
Physical therapy may be useful to help with balance, flexibility, accuracy of limb movements, and maintenance of strength. GPP
Occupational therapy may identify risks for people with ataxia as well as help minimize difficulties in the performance of
daily activities.
GPP
Routine orthopedic care is necessary to follow and treat orthopedic issues that can influence ataxia. GPP
1.2 Weakness
Recommendations Grade
Assessment of muscle weakness is an essential part of the functional evaluation of an individual with FRDA. GPP
Fatigue is a prevalent symptom in FRDA that may be included in quality of life assessments of individuals with FRDA. GPP
Physical therapy and exercise training may improve strength, motor performance and reduce fatigue. GPP
Muscle weakness may interfere with the clinical assessment of coordination and gait in individuals with FRDA. GPP
Medications improving mitochondrial function may improve muscle strength and reduce fatigue. GPP
1.3 Neuropathy
Recommendations Grade
Neuropathic pain may be treated with Gabapentin, Pregabalin, Lamotrigine, Amitriptyline or Duloxetine. C [20,21]
A detailed sensory assessment and examination will establish the extent of neuropathy. GPP
Protective foot care is important. GPP
Preventative measures such as review of daily activities, transfers and wheelchair positioning may reduce the incidence of
focal neuropathies.
GPP
1.4 Spasticity and muscle spasm
Recommendations Grade
People with FRDA may benefit from assessment for spasticity, pain and spasms (including nocturnal spasms) and incipient
or established contracture. This may guide treatment.
GPP
On implementation of an anti-spasticity intervention, individuals with FRDA may benefit from reassessment as the treatment
of spasticity can unmask weakness and cause deterioration in gait and standing transfers. Individuals should be warned of
this phenomenon before anti-spasticity interventions are commenced.
GPP
Aggravating factors such as infection, pain, constipation, diarrhea, dehydration and pressure sores should be considered and
treated in the context of acute onset or exacerbation of spasticity and/or ataxia.
GPP
Spasticity and spasms should be treated at an early stage, initially by non-pharmacological means. If these are unsuccessful,
pharmacological means such as the use of Baclofen, Tizanidine, Benzodiazepines, Dantrolene sodium, Gabapentin,
botulinum toxin injections, alcohol and phenol injections or intrathecal Baclofen pumps may be considered. The benefit of
such compounds must be balanced against adverse effects they might produce on other symptoms of FRDA (for example
ataxia). In the last resort, surgical options may be considered. The distribution of spasticity around the body may also
determine which intervention is chosen.
C [22-24]
Individuals with FRDA, families and caregivers should be educated to monitor the development of spasticity and incipient
contractures, and should be given an ongoing plan of exercises and passive or active stretching to be performed routinely
outside the clinical setting.
C [22]
1.5 Restless legs (RLS)
Recommendations Grade
People with FRDA should be specifically asked if they have RLS symptoms. B [25,26]
A full history of the symptoms should be taken from patients suspected of having RLS so that other confounding conditions
i.e. periodic leg movements can be excluded.
B [27]
Secondary causes of RLS should be excluded, in particular, a drug history should be taken and serum ferritin measurement
should be undertaken.
B [27]
Initial treatment of RLS should consider the needs of the patient, the severity of the symptoms, the relative significance of
the reported effects of the treatment and the level of dysfunction attributable to RLS.
A [28]
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Table 4 The neurological components of Friedreich ataxia (Continued)
1.6 Mobility
Recommendations Grade
Mobility, balance, core stability, trunk control, spasticity, foot position and strength should be assessed by a suitably qualified
physical therapist.
GPP
The impact of spasticity of lower limbs on mobility should be evaluated when assessing gait. GPP
Foot and ankle posture should be assessed by a suitably qualified physical therapist and treated proactively. D [5,29]
Strategies such as an appropriate exercise program, aquatic physical therapy and stretches may be implemented to prolong
ambulation and reduce the number of falls in people with FRDA.
D [30,31]
Individuals with FRDA dependent on a wheelchair for mobility may still benefit from rehabilitation to improve their mobility. D [31]
Botulinum toxin and prescription of ankle-foot orthotics may be useful in reducing the impact of spasticity during mobility
and will help maintain good foot alignment for mobility.
GPP
Gait aid provision may prolong the capacity to walk. A heavy/weighted gait-aid may be a beneficial for some individuals
with FRDA.
GPP
Standing frame and tilt table may be used to maintain foot alignment to enable independent transfers. GPP
An inpatient rehabilitation program may prolong mobility and transfer ability. D [31]
1.7 Dysarthria
Recommendations Grade
People with FRDA should undergo a comprehensive communication evaluation by a speech and language pathologist at
the time of diagnosis or symptom onset and thereafter undertake review assessments to monitor performance.
C [32]
Instruction in environmental modification may be beneficial for individuals with motor speech difficulties. C [33]
Participation in intensive and systematic behavior therapy may be beneficial to people with FRDA with dysarthria. C [33]
Traditional non-systematic behavioral therapy may not be helpful for mitigating the effects of progressive dysarthria. GPP
1.8 Dysphagia
Recommendations Grade
People with FRDA should undergo a comprehensive swallowing evaluation by a speech and language pathologist at the
time of diagnosis or symptom onset and thereafter to monitor performance.
D [34,35]
Instruction in environmental modification and compensatory postures may be beneficial for individuals with dysphagia. D [36-39]
Instruction in dietary modification may be beneficial for individuals with dysphagia. D [38,40,41]





Screening or testing as per country specific general vision screening guidelines should be applied to individuals with FRDA. GPP
Memantine, Acetazolamide, Aminopyridine, Clonazepam, Gabapentin or Ondansetron may be of benefit in treating square




Exclusion of a concomitant urinary tract infection and assessment of post micturition residual urine is recommended prior to
commencement of treatment.
C [43,44]
Antimuscarinic medications may be considered for people with FRDA displaying overactive bladder symptoms. GPP
Intradetrusor injections of Botulinum toxin A or suprapubic catheterization may be considered as alternative intervention. GPP





Consider modifying diet and lifestyle to optimize stool consistency and avoid fecal incontinence. GPP
Titrate appropriate laxatives to optimize gut transit, stool consistency and avoid fecal impaction. Consider the use of
prokinetic drugs.
GPP
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Table 4 The neurological components of Friedreich ataxia (Continued)
Avoid fecal incontinence by treating fecal impaction if present. Facilitate prompt rectal evacuation via use of manual





Individuals with FRDA may benefit from discussion regarding their sexual function. GPP
Reported sexual dysfunction should be investigated. GPP
Symptomatic management of erectile dysfunction involves the use of phosphodiesterase-5 inhibitors but should only be




People with FRDA should undergo a comprehensive auditory evaluation at the time of diagnosis and thereafter annually
undertake a hearing screen or sooner if warranted by a sudden change in auditory performance.
B [45]
Instruction in “listening tactics” may be beneficial for individuals with hearing difficulties. B [46]
FM-listening devices fitted by an audiologist may improve day-to-day listening and general communication in individuals
with FRDA.
B [47]
Conventional hearing aids and cochlear implants may not improve the hearing impairment related to FRDA. GPP
1.14 Cognition
Recommendations Grade
Consideration should be given to changes in cognitive function that may impact on independence. GPP
The impact of cognitive capacity on academic skills should be considered in academic environments. GPP
1.15 Rehabilitation
Recommendations Grade
Intensive inpatient rehabilitation is beneficial in improving function for people with FRDA. C [31]
People with FRDA may require a cardiologist opinion prior to undergoing aquatic physical therapy. GPP
Rehabilitation may be provided in various home or community based settings. GPP
Rehabilitation should be provided by allied health staff with expertise in neurological conditions. GPP
People with FRDA may benefit from maintenance rehabilitation and regular review of function. GPP
2 The heart, cardiovascular and respiratory systems in Friedreich Ataxia
2.1 The heart in Friedreich Ataxia
Recommendations Grade
Cardiac evaluation and non-drug therapy
An EKG and an echocardiogram should be performed at diagnosis and then at least annually. GPP
A Holter and/or Loop monitor assessment should be performed if an individual with FRDA has palpitations. GPP
Evaluation by a cardiologist should take place if an individual with FRDA has cardiac symptoms or abnormal results on
cardiac testing.
GPP
Evaluation by a cardiologist should take place prior to major surgery. GPP
Cardiac monitoring should take place during major surgery. GPP
Major surgery should be conducted in a center with cardiac intensive care facilities. GPP
Exercise therapy, including structured aerobic exercise and light weights, is recommended. GPP
Heavy weight training is not advised. GPP
Pharmacological therapy for slowing or prevention of deterioration of left ventricular contraction in asymptomatic individuals with
reduced ejection fraction
An angiotensin converting enzyme inhibitor (Enalapril, Ramipril, Lisinopril or Trandolapril) is first line therapy but if the
angiotensin converting enzyme inhibitor is not tolerated then an angiotensin 2 receptor blocker (Candesartan, Valsartan)
should be commenced instead (second line therapy).
C [48]
Beta blockers (Carvedilol, Bisoprolol or long acting Metoprolol) should be considered as an addition to an angiotensin
converting enzyme inhibitor or angiotensin 2 receptor blocker, particularly if the heart rate is >75/min.
C [48]
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Table 4 The neurological components of Friedreich ataxia (Continued)
Pharmacological therapy for treatment of symptomatic heart failure with reduced LV ejection fraction
A diuretic should be prescribed for fluid overload. C [48]
An angiotensin converting enzyme inhibitor (Enalapril, Ramipril, Lisinopril or Trandolapril) is first line therapy but if the
angiotensin converting enzyme inhibitor is not tolerated then an angiotensin 2 receptor blocker (Candesartan, Valsartan)
should be commenced instead (second line therapy).
C [48]
Beta blockers (Carvedilol, Bisoprolol or long acting Metoprolol) should be added (first line therapy) to the angiotensin
converting enzyme inhibitor or angiotensin 2 receptor blocker, however the role of beta blockers in children is less clear.
C [48]
Spironolactone or Eplerenone should be considered for individuals with New York Heart Association (NYHA) stage 3 or 4
symptoms.
C [48]
Calcium channel blockers with negative inotropic effects (Verapamil and Diltiazem) should be avoided. C [48]
Digoxin should be considered for control of ventricular response if atrial fibrillation is present. C [48]
Device therapy for subjects with symptomatic heart failure and reduced ejection fraction
Implantation of an automatic internal cardioverter defibrillator should be considered if left ventricular ejection fraction (LVEF)
is ≤35%, the individual has NYHA functional class 2 or 3 symptoms despite receiving optimal medical therapy, and the
individual has a reasonable expectation of survival with good functional status for more than 1 year.
C [49]
Cardiac resynchronization therapy should be considered in individuals with LVEF of ≤35%, sinus rhythm, a QRS duration
≥0.12 seconds and NYHA functional class 3 or 4 symptoms despite receiving optimal medical therapy.
C [49]
Antiarrhythmic agents for prevention of recurrence of atrial arrhythmias
Agents which may be considered for prevention of recurrence of atrial arrhythmias are a beta blocker (Metoprolol, Bisoprolol
or Carvedilol), Sotalol, Dofetilide or Amiodarone.
C [50]
Agents which should be avoided include Quinidine, Flecainide, Propafenone and Disopyramide due to their negatively
inotropic and/or pro-arrhythmic effects.
C [50]
Anticoagulation for atrial arrhythmias
Anticoagulation should not be commenced if the LVEF is normal and there are no other risk factors for thromboembolism C [50]
Anticoagulation with Warfarin or one of the novel anticoagulants (Dabigatran, Rivaroxaban or Apixaban) should be
considered in paroxysmal or permanent AF if one CHADS2 risk factor is present and will be generally indicated if more than
one CHADS2 risk factor is present.
C [50]
Anticoagulation with warfarin or one of the novel anticoagulants (Dabigatran, Rivaroxaban or Apixaban) is strongly
recommended in paroxysmal or permanent AF if there is reduced LVEF.
C [50]
Antiarrhythmic agents for prevention of recurrence of ventricular arrhythmias
A beta blocker (Metoprolol, Bisoprolol or Carvedilol) should be used, but Sotalol and Amiodarone are second-line options if
there is arrhythmia recurrence despite beta blocker use.
C [49]
Cardiac transplantation
It is recommended that individuals with FRDA should be considered for heart transplantation if they experience severe




Clinicians, caregivers and individuals with FRDA should be aware there is increased prevalence of obstructive sleep apnea
(OSA) as FRDA progresses.
C [51]
Annual evaluation of presence of sleep disordered breathing may be undertaken by administering of the Epworth Sleepiness
Scale and reporting of clinical symptoms.
C [51]
For individuals with FRDA there should be a lower threshold for referral to a Sleep Physician and for polysomnography. C [51]
Nasal continuous positive airway pressure therapy should be considered in the treatment of OSA. C [52]
2.3 Pain management and anesthesia
Recommendations Grading
Consideration should be given to appropriate management of peri-operative pain in people with FRDA. GPP
Consideration should be given to the use of nondepolarizing muscle relaxants, in particular accurate assessment of
neuromuscular block throughout anesthesia.
D [53,54]
Consideration should be given to avoiding risks associated with hyperkalemia. GPP
There should be careful monitoring of fluid balance and cardiovascular function in people with FRDA undergoing anesthesia. GPP
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Table 4 The neurological components of Friedreich ataxia (Continued)
3. Scoliosis
Recommendations Grading
Individuals with FRDA with a spinal curve between 20° and 40° and/or between the ages of 10–16 years should be observed
for curve progression.
GPP
Bracing may not reduce or stop the progression of curves however may be valuable in delaying surgical correction in the
young child.
D [55]
People with FRDA with a scoliosis >40° may be considered appropriate for surgical correction. D [56,57]
Consideration should be given to delaying surgical intervention in ambulant individuals with FRDA. D [55]
All people with FRDA considered for scoliosis surgery require extensive pre-operative evaluation and planning regarding




HbA1C may not be a good screening/diagnostic test in FRDA as it is not recommended in young individuals and in people
in whom diabetes may present acutely.
GPP
Blood glucose should be measured at least once a year. GPP
Oral glucose tolerance tests have a better sensitivity than fasting plasma glucose or HbA1c to detect early changes in
glucose metabolism, and enable earlier diagnosis of diabetes.
GPP
Diabetes treatment should be initiated early. GPP
Lifestyle changes (diet and exercise) should be implemented in all with diabetes. GPP
Insulin therapy should be initiated if diet and exercise alone do not achieve glucose control. GPP
5. Genetic issues
Recommendations Grading
Any individual in whom the diagnosis of FRDA is considered should undergo genetic testing for FRDA. GPP
Referral to a clinical geneticist or genetic counselor should be considered on diagnosis of FRDA. GPP
Requests for pre-symptomatic genetic testing are best managed on a case-by-case basis; there is no evidence to support
the routine provision or refusal of pre-symptomatic genetic testing for FRDA.
GPP
The committee did not reach consensus on the issue of whether it is appropriate to conduct presymptomatic testing in a
minor. Where a request for presymptomatic testing in a minor occurs, the individual/family should be referred to a team
with expertise in this field for discussion about pre-symptomatic genetic testing in which the risks and benefits of
pre-symptomatic genetic diagnosis are put forward. The risks and benefits from both the child’s and parents’ perspectives
should be carefully reviewed during the pre-test assessment.
GPP
A multidisciplinary approach to the pre-symptomatic testing process, with the additional involvement of a psychologist or
psychiatrist with expertise in pediatric and adolescent issues, and if necessary a bioethicist, should be considered.
GPP
All patients identified pre-symptomatically and their families would benefit from immediate post-test counseling and
psychosocial support and referral for appropriate neurological and cardiac surveillance.
GPP
Minors who have the maturity to do so, should be involved in the decision as to whether or not they are tested. GPP
There is no evidence to support routine use of anti-oxidant therapies, such as Idebenone in patients diagnosed
pre-symptomatically.
GPP
Carrier testing should be first undertaken on the closest relative. GPP
6. Friedreich Ataxia due to compound heterozygosity for a FXN Intron 1 GAA expansion and point mutation/insertion/deletion
Recommendation Grading
If a person compound heterozygous for a FXN GAA expansion and a point mutation/insertion/deletion has a similar
phenotype to those with FRDA due to homozygosity for GAA expansions, they should be managed as per the guidelines
in this document.
GPP
If spastic ataxia is the predominant phenotype, then the main management issue is that of spasticity and the guidelines for
management of spasticity should be followed.
GPP
It should never be assumed that other features of typical FRDA will not be present (e.g. cardiomyopathy, diabetes) and
therefore monitoring for these should take place.
GPP
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Table 4 The neurological components of Friedreich ataxia (Continued)
7 Pregnancy
Recommendations Grading
The availability of testing for carrier status of reproductive partners should be made known to couples where one member
has FRDA. If testing is requested, the carrier status of the unaffected partner should be established prior to conception in
order to advise the couple of the risk of having a child with FRDA and to offer appropriate counseling.
GPP
When possible, it is advisable for women to have children earlier in their disease course. GPP
Glucose tolerance testing should be performed between 24–28 weeks of gestation or earlier for individuals deemed to be
at high risk by their practitioner.
D [58]
Women with FRDA should have close monitoring by a cardiologist during pregnancy. GPP
Pregnant women with FRDA and deep venous thrombosis should be treated with Heparin as opposed to Warfarin. D [59]
Vaginal delivery can be expected for most pregnancies in women with FRDA. D [60]
Close fetal monitoring during delivery is recommended. D [61]
If Cesarean section is medically indicated, epidural or spinal anesthesia can generally be safely used in women with FRDA. D [62,63]
8 Issues related to quality of life
8.1 Quality of life
Recommendations Grading
Adherence to the guidelines for managing FRDA may improve quality of life. GPP
8.2 Mental health issues
Recommendations Grading
Individuals with FRDA require regular evaluation in terms of risks for developing depression and/or other mental health issues. GPP
Individuals with FRDA may benefit from regular counseling to assist in adjusting to transitional events and possibly prevent
the emergence of related depression.
GPP
Individuals with FRDA identified with depression should be treated with established interventions including counseling +/−
pharmacological agents.
GPP
The risk of suicide in individuals with FRDA should be considered and managed proactively. GPP
8.3 Provision of wheelchairs and seating systems
Recommendations Grading
Prescription of a manual or powered wheelchair or scooter should be preceded by an assessment of the home/school/work
and community environment the equipment will be used in.
GPP
A comprehensive prescription of a manual or powered wheelchair or scooter should be completed by a qualified clinician
familiar with the specific issues related to FRDA.
GPP
A validated assessment and evaluation tool for wheelchair and seating prescription may be used to guide the process of
prescription and evaluation.
GPP
In prescribing a manual wheelchair and seating system, functional capacity should not be impeded for the sake of an
anatomically correct seated posture.
GPP
Appropriate training should be provided regarding the safe use of the wheelchair or scooter in the home or community
environment.
GPP
Suitability of the seating and wheelchair system should be evaluated on an annual basis in adults and bi-annually in children. GPP
8.4 Independence issues
Recommendations Grading
Individuals with FRDA may benefit from a detailed assessment identifying barriers to independence. GPP
Compensatory or remedial intervention may improve independence in individuals with FRDA. GPP
8.5 Advance care planning and end of life care
Recommendations Grading
Professionals should facilitate advance care planning and documentation of advance care directives in individuals with FRDA. GPP
Advance care directives documented for individuals with FRDA should be regularly reviewed by the individual in conjunction
with their treating clinicians.
GPP
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Table 4 The neurological components of Friedreich ataxia (Continued)
8.6 Palliative care
Recommendations Grading
Neurology, rehabilitation and palliative care services should develop closely coordinated working links to support people
with FRDA from diagnosis to death, including:
• proper flow of communication and information for patients and their families
• a designated point of contact for each stage in the pathway.
GPP
Individuals with FRDA and a limited lifespan (for example, likely to die within 12 months) and/or distressing symptoms, and/or a need
for end-of-life planning generally benefit from a referral to a palliative care team.
GPP
An individual identified as being in the process of dying from FRDA may benefit from ongoing access to palliative care
services including symptom and pain control, psychological and spiritual support and specialist input if needed.
GPP
9 Potential medications/compounds for use in Friedreich Ataxia
Recommendations Grading
As there are no proven treatments that alter natural history it is not recommended that any pharmaceutical agent be
routinely prescribed to individuals with FRDA.
A [64-67]
Idebenone is the most studied pharmacological agent in FRDA. Studies to date indicate the use of Idebenone in individuals
with FRDA does not result in significant changes to neurological or cardiac status over an extended period of time.
A
[64,65,67-74]
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The molecular basis of Friedreich ataxia was established
in 1996 [8]. The time since this pivotal discovery has
seen an explosion in the understanding of the underlying
mutation and the pathogenesis of the condition, the
phenotype and potential pharmacological interventions.
Despite this surge of information, significant gaps re-
main in understanding the best clinical interventions for
people with FRDA. In the absence of treatments that
lessen the impact of the condition, it is crucial that ap-
propriate clinical intervention is explored and docu-
mented. This paper has reported the methodology and
outcome of developing clinical management guidelines
for people with FRDA. In so doing it has highlighted the
disparate nature of FRDA requiring considerable depth
and breadth in terms of clinical management expertise.
The principle purpose of clinical management guide-
lines is to provide “systematically developed statements
to assist the practitioner and the patient to make deci-
sions about appropriate health care for specific clinical
circumstances” [75]. In addition clinical management
guidelines play a significant role in identifying the gaps
in the evidence and providing direction for ongoing
high-quality studies that will underpin future iterations
of the guidelines. Sixty-two percent of recommendations
are based on expert opinion or good practice. For ex-
ample areas such as the management of diabetes melli-
tus in FRDA, the complexity of genetic issues associated
with symptomatic and presymptomatic testing, sexual
function and quality of life have little evidence to reliably
inform recommendations. In addition, areas such as the
management of heart issues, dysarthria, dysphagia and
scoliosis have low quality evidence guiding intervention.
Whilst the development of these guidelines provides a
critical first step in the provision of appropriate clinical
care for people with FRDA, it also highlights the urgencyof undertaking high-quality clinical studies that will en-
sure the delivery of optimum intervention for people
with FRDA. These guidelines will be reviewed every
three years and it is hoped subsequent iterations will rely
less on expert opinion and more on high quality clinical
studies.
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